New hope to protect transplanted hearts from deadly protein buildup
NCT ID NCT05489523
Summary
This study is testing if the drug tafamidis is safe and helpful for people who have already received a heart transplant because of a serious disease called ATTR cardiac amyloidosis. The disease causes harmful proteins to build up and damage organs. Even after a heart transplant, these proteins can still cause problems in other parts of the body. Researchers want to see if tafamidis can stabilize these proteins and prevent further damage in 25 stable transplant patients over 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai
RECRUITINGBeverly Hills, California, 90211, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.